Brokerages Expect Alpine Immune Sciences Inc (NASDAQ:ALPN) Will Announce Quarterly Sales of $280,000.00

Brokerages expect that Alpine Immune Sciences Inc (NASDAQ:ALPN) will post sales of $280,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $250,000.00 to $300,000.00. The business is expected to issue its next quarterly earnings results on Monday, March 16th.

On average, analysts expect that Alpine Immune Sciences will report full-year sales of $1.03 million for the current year, with estimates ranging from $860,000.00 to $1.16 million. For the next financial year, analysts forecast that the business will post sales of $1.10 million, with estimates ranging from $1.00 million to $1.20 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Wednesday, November 13th. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. The company had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.38 million.

A number of equities research analysts have recently weighed in on ALPN shares. Zacks Investment Research raised shares of Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Monday, January 6th. Piper Jaffray Companies dropped their price objective on shares of Alpine Immune Sciences to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $9.56.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Alpine Immune Sciences by 67.7% during the second quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock valued at $853,000 after buying an additional 81,800 shares during the last quarter. Hikari Power Ltd boosted its holdings in Alpine Immune Sciences by 52.9% in the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock valued at $735,000 after purchasing an additional 64,224 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Alpine Immune Sciences by 10.8% in the second quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock valued at $447,000 after purchasing an additional 10,400 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Alpine Immune Sciences in the second quarter valued at $90,000. 46.80% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ALPN opened at $4.25 on Wednesday. The firm has a market capitalization of $81.98 million, a PE ratio of -1.62 and a beta of 1.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.84 and a quick ratio of 3.84. Alpine Immune Sciences has a 1-year low of $2.25 and a 1-year high of $8.24. The company’s fifty day moving average price is $3.56 and its 200-day moving average price is $3.76.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

See Also: Inverted Yield Curve

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply